InvestorsHub Logo
Followers 554
Posts 44859
Boards Moderated 3
Alias Born 01/31/2010

Re: ALERTS100%to10000%GAIN post# 30229

Wednesday, 02/25/2015 1:19:22 AM

Wednesday, February 25, 2015 1:19:22 AM

Post# of 33416
***HBRM***A TABLE POUNDER!!!*** The Company Starts Sales on Amazon Europe in the First Quarter of 2015


January 08, 2015 12:18 ET | Source: Herborium Group, Inc.

Fort Lee, New Jersey, USA, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc.(OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company providing unique, all botanical medicines (Botanical Therapeutics®), announced today that its Amazon sales grew 54% over sales for the same period in 2013. This very significant increase in revenue results from a 25% increase in the number of orders and a 37% increase in the average value of the order. The increase in the average value of the order is especially significant since it indicates a growing consumer confidence in Herborium and its products.

The overall growth in revenues, increase in number of customers and the average order value for Amazon based sales represent a pivotal factor in Herborium's decision to join Amazon in Europe through its UK Gateway in the first quarter of 2015. Amazon sales in Europe surpassed $20 billion and are growing on average 20% a year since 2011.

"Herborium's Amazon US sales growth in 2014 confirms our expectations for a very successful end of 2014. Company's financial results for 2014 should be announced shortly.

We expect the growth and profitability of our novel, all natural medicines - Botanical Therapeutics®" to continue in 2015 ", commented Dr. Agnes P. Olszewski, CEO and Chairwoman of Herborium Group.

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, and www.acnease.com.

Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
Contact Information:
Herborium Group, Inc.
Email:
Tel.201.849.4431
- See more at: http://globenewswire.com/news-release/2015/01/08/696055/10114749/en/Herborium-Increases-its-Sales-on-Amazon-54-Over-2013.html#sthash.YOb4iaK8.HvBZhtrh.dpuf

REMEMBER MY ALERTS ARE OPINIONS AND NOT RECOMMENDATIONS TO BUY OR SELL A SECURITY. IM NOT A LICENSED INVESTMENT ADVISER . DANGER WARNING

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.